Mitochondrial DNA haplogroups and highly active antiretroviral therapy-related lipodystrophy

Clinical Infectious Diseases

Volumn 47, Issue 7, 2008, Pages 962-968

  Nasi, Milena ^a   Guaraldi, Giovanni ^b   Orlando, Gabriella ^b   Durante, Caterina ^a   Pinti, Marcello ^a   Nemes, Elisa ^a   Nardini, Giulia ^b   Passarino, Giuseppe ^c   Cocchi, Marina ^a   Esposito, Roberto ^b   Mussini, Cristina ^b   Cossarizza, Andrea ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c UNIVERSITY OF CALABRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; MITOCHONDRIAL DNA; STAVUDINE; TENOFOVIR;

ACID BASE BALANCE; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY FAT DISTRIBUTION; CD4 LYMPHOCYTE COUNT; EUROPEAN AMERICAN; FEMALE; GENETIC POLYMORPHISM; GLUCOSE ASSAY; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; POINT MUTATION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; DNA, MITOCHONDRIAL; FEMALE; HAPLOTYPES; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; POLYMORPHISM, GENETIC;

EID: 52449098059     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591706     Document Type: Article

References (40)

1. Cossarizza A, Kalashnikova G, Grassilli E, et al. Mitochondrial modifications during rat thymocyte apoptosis: a study at the single cell level. Exp Cell Res 1994; 214:323-30.
2. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305:626-9.
3. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005; 39:359-407.
4. Torroni A, Huoponen K, Francalacci P, et al. Classification of European mtDNAs from an analysis of three European populations. Genetics 1996; 144:1835-50.
5. De Benedictis G, Rose G, Carrieri G, et al. Mitochondrial DNA inherited variants are associated with successful aging and longevity in humans. FASEB J 1999; 13:1532-6.
6. Crispim D, Canani LH, Gross JL, Tschiedel B, Souto KE, Roisenberg I. The European-specific mitochondrial cluster J/T could confer an increased risk of insulin-resistance and type 2 diabetes: an analysis of the m.4216T>C and m.4917A>G variants. Ann Hum Genet 2006; 70:488-95.
7. van der Walt JM, Dementieva YA, Martin ER, et al. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett 2004; 365:28-32.
8. Lewis W, Dalakas MC. Mitochondrial toxicity of antiviral drugs. Nat Med 1995; 1:417-22.
9. Galluzzi L, Pinti M, Guaraldi G, et al. Altered mitochondrial RNA production in adipocytes from HIV-infected individuals with lipodystrophy. Antivir Ther 2005; 10(Suppl 2):M91-9.
10. Galluzzi L, Pinti M, Troiano L, et al. Changes in mitochondrial RNA production in cells treated with nucleoside analogues. Antivir Ther 2005; 10:191-5.
11. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-96.
12. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
13. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002; 16:1341-9.
14. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-30.
15. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12:1735-44.
16. Wold S, Esbensen K, Geladi P. Principal component analysis. Chemometrics Intell Lab Syst 1987; 2:37-52.
17. Lugli E, Pinti M, Nasi M, et al. Subject classification obtained by cluster analysis and principal component analysis applied to flow cytometric data. Cytometry A 2007; 71:334-44.
18. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-60.
19. Cossarizza A, Moyle G. Antiretroviral nucleoside and nucleotide analogues and mitochondria. AIDS 2004; 18:137-51.
20. Ferraresi R, Troiano L, Rossi D, et al. Mitochondrial membrane potential and nucleosidic inhibitors of HIV reverse transcriptase: a cytometric approach. Mitochondrion 2004; 4:271-8.
21. Pinti M, Salomoni P, Cossarizza A. Anti-HIV drugs and the mitochondria. Biochim Biophys Acta 2006; 1757:700-7.
22. Troiano L, Ferraresi R, Lugli E, et al. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007; 2:2719-27.
23. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13:2261-7.
24. Mussini C, Pinti M, Bugarini R, et al. Effect of treatment interruption monitored by CD4 cell count on mitochondrial DNA content in HIV-infected patients: a prospective study. AIDS 2005; 19:1627-33.
25. Cossarizza A, Riva A, Pinti M, et al. Increased mitochondrial DNA content in peripheral blood lymphocytes from HIV-infected patients with lipodystrophy. Antivir Ther 2003; 8:315-21.
26. + T cell count after antiretroviral therapy in drug-naive HIV-positive patients. Immunogenetics 2005; 57:628-35.
27. Fellay J, Shianna KV, Ge D, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-7.
28. Wallace DC, Brown MD, Lott MT. Mitochondrial DNA variation in human evolution and disease. Gene 1999; 238:211-30.
29. Wallace DC. Mitochondrial DNA sequence variation in human evolution and disease. Proc Natl Acad Sci USA 1994; 91:8739-46.
30. Mishmar D, Ruiz-Pesini E, Golik P, et al. Natural selection shaped regional mtDNA variation in humans. Proc Natl Acad Sci USA 2003; 100:171-6.
31. Niemi AK, Hervonen A, Hurme M, Karhunen PJ, Jylha M, Majamaa K. Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum Genet 2003; 112:29-33.
32. van der Walt JM, Nicodemus KK, Martin ER, et al. Mitochondrial polymorphisms significantly reduce the risk of Parkinson disease. Am J Hum Genet 2003; 72:804-11.
33. Ferraresi R, Troiano L, Roat E, et al. Protective effect of acetyl-Lcarnitine against oxidative stress induced by antiretroviral drugs. FEBS Lett 2006; 580:6612-6.
34. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA. Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2′,3′-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol 2007; 204:29-38.
35. Luke C, Cornely OA, Fricke J, Lehrer E, Bartz-Schmidt KU. Late onset of Leber's hereditary optic neuropathy in HIV infection. Br J Ophthalmol 1999; 83:1204-5.
36. Shaikh S, Ta C, Basham AA, Mansour S. Leber hereditary optic neuropathy associated with antiretroviral therapy for human immunodeficiency virus infection. Am J Ophthalmol 2001; 131:143-5.
37. Hulgan T, Haas DW, Haines JL, et al. Mitochondrial haplogroups and peripheral neuropathy during antiretroviral therapy: an adult AIDS clinical trials group study. AIDS 2005; 19:1341-9.
38. Hilsenbeck SG, Friedrichs WE, Schiff R, et al. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst 1999; 91:453-9.
39. Craig JC, Eberwine JH, Calvin JA, Wlodarczyk B, Bennett GD, Finnell RH. Developmental expression of morphoregulatory genes in the mouse embryo: an analytical approach using a novel technology. Biochem Mol Med 1997; 60:81-91.
40. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.